BidaskClub downgraded shares of XBiotech (NASDAQ:XBIT) from a strong-buy rating to a buy rating in a report released on Thursday.
Separately, ValuEngine raised shares of XBiotech from a hold rating to a buy rating in a research report on Monday, January 7th.
XBIT traded up $0.67 on Thursday, reaching $9.76. 400 shares of the company traded hands, compared to its average volume of 169,602. XBiotech has a 52-week low of $2.13 and a 52-week high of $10.88.
Several institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in XBiotech during the 4th quarter valued at $80,000. Vanguard Group Inc raised its stake in XBiotech by 5.5% during the 3rd quarter. Vanguard Group Inc now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after purchasing an additional 43,648 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in XBiotech by 5.5% during the 3rd quarter. Vanguard Group Inc. now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after purchasing an additional 43,648 shares during the last quarter. Institutional investors and hedge funds own 3.12% of the company’s stock.
XBiotech Company Profile
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.